Gilead Sciences (GILD) Q4 Revenue Tops Views, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/7/2026
- Wall Street ends lower, off record highs, as Treasury yields climb
- Want to be a stock market bear? BCA says watch potential U.S. tax increases
- SpaceX seeks $40bn in financing for Nvidia chip purchase
- Chip stock could soar nearly 200%, analyst says: "If you don’t buy it, they will"
- Musk rules out TSMC role in Terafab operations; Intel gains
- HubSpot to cut 7% of workforce in restructuring plan
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- Sportradar to sell Synergy Sports coaching unit for $170M
- Caribou Biosciences to halt CAR-T programs, explore sale
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
Bullish Options Positioning in Gilead Sciences (GILD) Targets Upside in Shares Over the Coming Months -Susquehanna
February 7, 2018 2:49 PM ESTSusquehanna options strategist Alison Edwards notes bullish options positioning in Gilead Sciences (NASDAQ: GILD), as an opening investor bought 10,000 Mar 85 Calls for $2.20
... More


